BioCentury | Mar 31, 2021
Finance

March 31 Quick Takes: Muted reception for Achilles in market debut; plus BridgeBio-Helsinn, Scribe, Outpace, OnQuality, AffaMed, Treos

Achilles Therapeutics Inc. (NASDAQ:ACHL) briefly traded above its $18 IPO price before ceding ground in its first day of trading, settling to $16.55 in trading Wednesday. The clinical T cell therapeutics developer raised $175.5 million through...
BioCentury | Mar 31, 2021
Regulation

March 31 Quick Takes: Basket of EU approvals includes MS, SMA drugs; plus Amarin, AbbVie, Cara-Vifor

...from Ipsen (Euronext:IPN; Pink:IPSEY) and Exelixis Inc. (NASDAQ:EXEL), which targets c-MET, RET and FLT1, VEGFR-2 and FLT4...
...gene-related peptidec-MET (MET; HGFR) – c-Met receptor tyrosine kinaseFLT1 (VEGFR-1) – Vascular endothelial growth factor receptor 1FLT4 (VEGFR-3) – Vascular endothelial growth factor receptor...
...– Vascular endothelial growth factor receptor 3KOR(OPRK1) - Kappa opioid receptorPDGFRA (PDGFR2; CD140A) - Platelet derived growth factor receptor AVEGFR-2 (KDR/Flk-1...
BioCentury | Mar 31, 2021
Emerging Company Profile

Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline

...of first negotiation and refusal to GB-102, a pan-VEGF...
BioCentury | Mar 27, 2021
Translation in Brief

Lentigen’s trispecific CAR Ts; plus a bispecific antiviral COVID-19 mAb, Wild Biotech, Kancera and more

...comprising lethally irradiated tumor cells that overexpress VEGF-C...
...– Programmed cell death 1 VEGF-C (VRP) – Vascular endothelial growth factor...
...AB Lycia Therapeutics Inc. Stanford University Wild Biotech Ltd. Vascular endothelial growth factor C (VEGF-C...
BioCentury | Mar 11, 2021
Regulation

Tivozanib, at last, is Aveo’s first approved drug in the U.S.

...2017 for first-line treatment of adults with advanced RCC, and for RCC patients who are VEGF...
...for tivozanib and 8% for sorafenib. TARGETSmTOR (FRAP; RAFT1) – Mammalian target of rapamycinVEGFVascular endothelial growth factor Jeff...
BioCentury | Feb 27, 2021
Regulation

Nod for Roche’s oral SMA drug among CHMP’s latest opinions: Data Byte

...AXL receptor tyrosine kinasec-MET (MET; HGFR) – c-Met receptor tyrosine kinaseFLT1 (VEGFR-1) – Vascular endothelial growth factor receptor 1FLT4 (VEGFR-3) – Vascular endothelial growth factor receptor...
...1 SMN2 – Survival of motor neuron 2 centromericVEGFVascular endothelial growth factorVEGFR-2 (KDR/Flk-1) – Vascular endothelial growth factor receptor 2 Sandi...
BioCentury | Feb 13, 2021
Product Development

Feb. 12 Quick Takes: G1’s first approval is first in class; plus Seagen, Denali, Roche and Takeda

...detailed data from four Phase III studies of bispecific mAb faricimab, which targets ANG2 and VEGF...
...hematopoietic stem cell transplantation recipients with CMV. TARGETSANG2 (ANGPT2) – Angiopoietin 2IDS – Iduronate 2-sulfataseVEGF-A – Vascular endothelial growth factor...
BioCentury | Feb 10, 2021
Product Development

First-line RCC immunotherapy combinations shine at ASCO GU

Competition in first-line renal cell carcinoma remains tight as new checkpoint combinations read out in Phase III. With two years of progression free survival, the latest combination to join the bunch ...
BioCentury | Feb 9, 2021
Product Development

Feb. 8 Quick Takes: FDA approves TG’s lymphoma therapy; plus uniQure, Astellas, BMS, Viiv, Avrobio and Veru

FDA approved Ukoniq umbralisib from TG Therapeutics Inc. (NASDAQ:TGTX) to treat relapsed or refractory marginal zone lymphoma following anti-CD20 treatment, or relapsed or refractory follicular lymphoma in a fourth-line setting. TG believes the once-daily oral...
BioCentury | Feb 9, 2021
Product Development

Opdivo makes rare hit in adjuvant muscle-invasive bladder cancer

...Programmed cell death 1 ligand 1VEGFR – Vascular endothelial growth factor receptor Lauren...
Items per page:
1 - 10 of 4414